Maegim한국어

큐라티스

348080KOSDAQSector: Pharma & Biotech
₩309 0.00%Market cap ₩35.7BAs of Jul 21, 2026 close · updated once daily
C
Grade C42.4 ptsTop 67% of 2,523 stocks
Financial strength
33.2
Growth momentum
63.7
Price attractiveness
37.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

33.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
23.7%
Above median · Top 23.4% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
122.5%
Below median · Top 67.3% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-420.6%
Below median · Top 88.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-67.0%
Below median · Top 88% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

2

Growth momentum

63.7
How much did revenue grow in a year?
Revenue growth (YoY)
557.3%
Above median · Top 1.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-33.6%
Below median · Top 93.7% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
47.6%
Above median · Top 21.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
53.9%
Above median · Top 28.8% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

37.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 96.1% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.81x
Above median · Top 28.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15